Indacaterol
Chemical compound
From Wikipedia, the free encyclopedia
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist[5] developed by Novartis. It needs to be taken only once a day,[6] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.[7]
- EU EMA: by INN
- US DailyMed: Indacaterol
category
- AU: B3
| |
 | |
| Clinical data | |
|---|---|
| Trade names | Onbrez, Arcapta |
| AHFS/Drugs.com | International Drug Names |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 43-45 % (inhaled) |
| Metabolism | UGT1A1, CYP3A4 |
| Elimination half-life | 40-56 h |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.218.577 |
| Chemical and physical data | |
| Formula | C24H28N2O3 |
| Molar mass | 392.499 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Medical uses
A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.[8]
Pharmacology
History
It was approved by the European Medicines Agency (EMA) under the brand name Onbrez Breezhaler on November 30, 2009,[11] and by the United States Food and Drug Administration (FDA), under the brand name Arcapta Neohaler, on July 1, 2011.[12][13] In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler to Sunovion Pharmaceuticals.[14]